Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorKong, Qi-
Autor(es): dc.creatorWu, Yue-
Autor(es): dc.creatorGu, Yu-
Autor(es): dc.creatorLv, Qi-
Autor(es): dc.creatorQi, Feifei-
Autor(es): dc.creatorGong, Shuran-
Autor(es): dc.creatorChen, Xiuping-
Data de aceite: dc.date.accessioned2026-02-09T11:41:04Z-
Data de disponibilização: dc.date.available2026-02-09T11:41:04Z-
Data de envio: dc.date.issued2020-07-06-
Data de envio: dc.date.issued2020-07-06-
Data de envio: dc.date.issued2020-08-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41720-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0753332220305084-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1145137-
Descrição: dc.descriptionBackground Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified. Methods We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform. Results PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate. Conclusion PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceBiomedicine & Pharmacotherapy-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectTraditional Chinese herbs-
Palavras-chave: dc.subjectTargeted therapy-
Palavras-chave: dc.subjectNetwork pharmacology-
Título: dc.titleAnalysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.